Thyroid Cancer Prevalent Among Transgender Female Veterans
By Lori Solomon HealthDay Reporter
WEDNESDAY, Nov. 29, 2023 -- There is a high prevalence of thyroid cancer among transgender female veterans, according to a study presented at the annual meeting of the American Thyroid Association, held from Sept. 27 to Oct. 1 in Washington, D.C.
John Christensen, M.D., from the University of California Davis, and colleagues examined the prevalence of thyroid cancer in transgender female veterans (January 2017 to January 2022). The authors reviewed individual charts to identify trends in clinical presentation.
The researchers found that the prevalence of thyroid cancer among transgender female veterans was 0.341 percent, with 29 patients having papillary, seven having follicular, and thee having Hürthle cell carcinoma. At the time of diagnosis, the average age was 53.8 years. Nearly three in 10 patients (29.4 percent) had extrathyroidal disease at diagnosis. Of the 11 participants receiving estrogen gender-affirming hormone therapy at diagnosis, treatment began an average of 6.85 years before diagnosis.
"About one-third of our patients had been receiving estrogen for an average of over five years before diagnosis, which suggests estrogen gender-affirming hormone therapy is a potentially important risk factor," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2023-11-30 00:33
Read more

- Texas County Reports Measles Outbreak Among Unvaccinated Children
- Lifetime Cancer Risk Might Be Set Before You're Born
- Smog During Pregnancy Threatens Newborn Health
- New York Sues Vape Companies for Marketing to Youth, Violating Flavor Ban
- Mass Shootings That Claim Most Kids' Lives Are Done by Family Members
- American Stroke Association, Feb. 5-7
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions